Edward Kim, a board certified psychiatrist, has joined Sweden-based Orexo AB as chief medical officer to lead development of treatments for substance use disorders and other mental health issues. He will be located at Orexo’s US subsidiary in Morristown, New Jersey. Dr Kim was previously head of medical affairs at Biohaven Pharmaceuticals, which was acquired by Pfizer Inc in October. He has also been therapeutic area leader for schizophrenia at Janssen Pharmaceutical Companies.
Dr Kim received his medical degree from Thomas Jefferson University and a bachelor’s degree in biology from Harvard University, both in the US.
Orexo announced the appointment on 26 October 2022.
Copyright 2022 Evernow Publishing Ltd